WVE
Wave Life Sciences Ltd. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -7.1% ·
share flow +0.5% ·
net new positions -7.7%
· formula
Concentrated accumulation: rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 87 | 0 | 83.58M | $485.57M | +8 | −9 |
| Q1 2026 | 91 | +3 | 75.16M | $544.65M | +10 | −7 |
| Q4 2025 | 87 | +2 | 83.62M | $1.42B | +4 | −2 |
| Q3 2025 | 17 | 0 | 51.40M | $376.26M | +2 | −3 |
| Q2 2025 | 15 | -1 | 44.33M | $288.15M | +1 | −2 |
| Q1 2025 | 13 | -1 | 25.22M | $203.80M | n/a | −1 |
| Q4 2024 | 14 | -1 | 25.08M | $310.31M | n/a | −1 |
| Q3 2024 | 14 | +2 | 20.71M | $169.87M | +2 | n/a |
| Q2 2024 | 12 | n/a | 14.01M | $69.91M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Adage Capital Partners ✦ | 12.52M | +30.1% | $101.13M | 0.2% | ▲ Add | 4 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 4.13M | -19.1% | $33.33M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 3 | Geode Capital Management ✦ (passive) | 2.59M | +4.9% | $20.95M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 4 | PRIMECAP Management ✦ | 2.51M | -0.5% | $20.26M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 5 | State Street Global Advisors ✦ (passive) | 2.42M | -0.4% | $19.54M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 6 | Wellington Management ✦ | 299.67K | -3.7% | $2.42M | 0.0% | ▼ Trim | 4 | SEC ↗ ×4 |
| 7 | Two Sigma Investments ✦ | 241.71K | -38.3% | $1.95M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 8 | Renaissance Technologies ✦ | 210.22K | +406.3% | $1.70M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 9 | D. E. Shaw & Co. ✦ | 106.55K | -85.1% | $860,956 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 10 | Norges Bank ✦ (passive) | 100.00K | 0.0% | $808,000 | 0.0% | Held | 3 | SEC ↗ |
| 11 | Citadel Advisors ✦ | 61.96K | +1825.3% | $500,604 | 0.0% | ▲ Add | 4 | SEC ↗ |
| 12 | Millennium Management ✦ | 26.22K | -97.8% | $211,874 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 16.09K | -11.8% | $130,031 | 0.0% | ▼ Trim | 4 | SEC ↗ ×3 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Marshall Wace | $2.27M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 230 holders, 172.04M shares, $1.17B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 12.70K sh · $67,183
Director · 3.86K sh · $23,223
Director · 432 sh · $2,596
Director · 7.00K sh · $42,070
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
16.8% of class · View original SEC filing ↗